Research Updates Archives • Page 8 of 8 • FRAXA Research Foundation

FRAXA Announces 2012 Fragile X Research Awards

April 3, 2012

In 2012, Fragile X Research was awarded $1,132,923 in new program grants, postdoctoral fellowships, and renewals. We are funding over $846,000 in new projects; renewals totalling $285,678 and will increase as additional projects reach their one year mark. View report here.

Fragile X Research Grants and Fellowships Funded 2011

April 7, 2011

In 2011, FRAXA awarded over $1 million for Fragile X research, funding top new projects to speed discovery of effective treatments and, ultimately, a cure.

FRAXA 2010 Research Awards Funded

July 11, 2010

FRAXA awarded over $1.5 million in 2010 for cutting-edge Fragile X research and fellowships, funding scientists working toward effective new treatments.

Results of First Fenobam Trial in Adults with Fragile X Published

July 1, 2009

We are pleased to announce the publication of positive results of a Phase IIa clinical trial of fenobam in Fragile X. Fenobam belongs to a class of compounds known as mGluR5 antagonists. Neuropharm, a specialty pharmaceutical company based in the U.K., received Orphan Drug Designation in the US in 2006 for fenobam in the treatment of Fragile X, after acquiring rights to relevant data on the compound from FRAXA. This trial was conducted in the US by Drs. Randi Hagerman of the UC Davis MIND Institute and Elizabeth Berry-Kravis of the RUSH University Medical Center, and initial results were first announced last summer.

3 Researchers Honored at FRAXA Investigators Meeting

October 4, 2008

Over 150 scientists from around the world gathered at FRAXA’s 2008 Investigators Meeting to share discoveries and speed treatments for Fragile X syndrome.

Iryna Ethell, PhD, at University of California

Researchers Propose Minocycline to Treat Fragile X

October 4, 2008

This team has found that an available drug called minocycline, an inhibitor of mmp9, might also be used to treat Fragile X. Clinical trials later tested this.